Search
Pidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023. … [L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the
Xenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigationalThey undergo a process that increases nuclear polarization up to five orders of magnitude, leading to a higher MRI signal. … Hyperpolarized Xenon-129 (Xe-129) is a contrast agent used in the lung's clinical magnetic resonance imaging (MRI).
Synonyms: Xenon, isotope of mass 129m(8.88 d)Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalHunter syndrome is a rare, X-linked lysosomal storage disorder caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), which leads to the toxic accumulation of glycosaminoglycans (GAGs) throughout … Tividenofusp alfa is a recombinant human IDS fused to a monoclonal antibody that targets the human insulin receptor (HIR), utilizing receptor-mediated transcytosis to gain access to the central nervous
Synonyms: 676>S, L 678>A, Y, - L-iduronate sulfate sulfatase, EC:3.1.6.13) pro-protein (1-525), fused via the peptide linker 526 GGGGS 530 to a human immunoglobulin G1 C-terminal Fc fragment (531-757) variant (L 544>A, L 545>A, TPegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigationalPegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized … to a different glycosylation pattern.
Asciminib
go.drugbank.com/drugs/DB12597ApprovedInvestigational[L38995,A241055] Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000] … Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[L41635] CYP51, also known as 14α demethylase, participates in the formation of ergosterol, a compound that plays a vital role in the integrity of cell membranes. … [L41635] This drug was approved by the FDA on April 26, 2022.[L41645]
Ensartinib
go.drugbank.com/drugs/DB14860ApprovedInvestigational[A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC). … Non-small cell lung cancer (NSCLC) is one of the most frequent subtypes of lung cancers and encompasses a variety of different lung cancers, with notable ones being adenocarcinoma, squamous cell carcinoma
SCIB1
go.drugbank.com/drugs/DB18439InvestigationalIt consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells.
AdimrSC-2f
go.drugbank.com/drugs/DB16436InvestigationalA phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548]. … The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].